发布求助

文献互助智能选刊最新文献

Early serum PreS1 levels are predictive of HBsAg loss in interferon-alpha treated children with HBeAg-positive chronic hepatitis B

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-10-16 DOI:10.1016/j.cca.2025.120661

Peiyao Fan , Fuchuan Wang , Yi Dong , Jianguo Yan , Lili Cao , Yinjie Gao , Zhiqiang Xu , Yanwei Zhong , Min Zhang

{"title":"Early serum PreS1 levels are predictive of HBsAg loss in interferon-alpha treated children with HBeAg-positive chronic hepatitis B","authors":"Peiyao Fan , Fuchuan Wang , Yi Dong , Jianguo Yan , Lili Cao , Yinjie Gao , Zhiqiang Xu , Yanwei Zhong , Min Zhang","doi":"10.1016/j.cca.2025.120661","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aim(s)</h3><div>The PreS1 surface antigen of large surface proteins (LHBs) plays an important role in predicting clinical outcomes in adults with chronic hepatitis B (CHB). This study aimed to determine whether PreS1 levels can predict HBsAg loss in children with HBeAg-positive CHB undergoing a 48-week interferon-alpha (IFN-α) therapy protocol.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of 133 children with CHB. Biomarkers and clinical outcomes were assessed every three months. The area under the receiver operating characteristic (AUROC) curve was calculated to evaluate the predictive value of different biomarkers for HBsAg loss at the 48-week end-point.</div></div><div><h3>Results</h3><div>At the end of the 48-week IFN-α therapy, HBsAg loss was achieved in 16.5 % (22/133) of patients. PreS1 levels were positively correlated with serum quantitative HBsAg (qHBsAg) and hepatitis B virus (HBV) DNA levels. At baseline, only the PreS1/qHBsAg ratio predicted HBsAg loss at week 48 (AUROC = 0.661, <em>p</em> = 0.015). At week 12, PreS1 levels also predicted HBsAg loss at week 48 (AUROC = 0.875, <em>p</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>Early serum PreS1 levels and the PreS1/qHBsAg ratio may serve as useful predictors of HBsAg loss in children with CHB receiving IFN-α therapy, providing potential guidance for clinical decision-making.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120661"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125005406","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aim(s)

The PreS1 surface antigen of large surface proteins (LHBs) plays an important role in predicting clinical outcomes in adults with chronic hepatitis B (CHB). This study aimed to determine whether PreS1 levels can predict HBsAg loss in children with HBeAg-positive CHB undergoing a 48-week interferon-alpha (IFN-α) therapy protocol.

Methods

We conducted a retrospective analysis of 133 children with CHB. Biomarkers and clinical outcomes were assessed every three months. The area under the receiver operating characteristic (AUROC) curve was calculated to evaluate the predictive value of different biomarkers for HBsAg loss at the 48-week end-point.

Results

At the end of the 48-week IFN-α therapy, HBsAg loss was achieved in 16.5 % (22/133) of patients. PreS1 levels were positively correlated with serum quantitative HBsAg (qHBsAg) and hepatitis B virus (HBV) DNA levels. At baseline, only the PreS1/qHBsAg ratio predicted HBsAg loss at week 48 (AUROC = 0.661, p = 0.015). At week 12, PreS1 levels also predicted HBsAg loss at week 48 (AUROC = 0.875, p < 0.001).

Conclusions

Early serum PreS1 levels and the PreS1/qHBsAg ratio may serve as useful predictors of HBsAg loss in children with CHB receiving IFN-α therapy, providing potential guidance for clinical decision-making.

查看原文本刊更多论文

早期血清PreS1水平可预测干扰素治疗的hbeag阳性慢性乙型肝炎患儿的HBsAg损失。

背景与目的：大表面蛋白（LHBs）的PreS1表面抗原在预测成人慢性乙型肝炎（CHB）的临床预后中起重要作用。本研究旨在确定PreS1水平是否可以预测hbeag阳性CHB患儿接受48周干扰素-α (IFN-α)治疗后的HBsAg损失。方法：对133例慢性乙型肝炎患儿进行回顾性分析。每三个月评估一次生物标志物和临床结果。计算受试者工作特征（AUROC）曲线下面积，以评估不同生物标志物对48周终点HBsAg损失的预测价值。结果：在48周IFN-α治疗结束时，16.5% %（22/133）的患者实现了HBsAg损失。PreS1水平与血清定量HBsAg （qHBsAg）和乙型肝炎病毒（HBV） DNA水平呈正相关。在基线时，只有PreS1/qHBsAg比值能预测第48周的HBsAg损失（AUROC = 0.661,p = 0.015）。12周时，PreS1水平也可预测48周时的HBsAg损失（AUROC = 0.875,p ）。结论：早期血清PreS1水平和PreS1/qHBsAg比值可作为接受IFN-α治疗的CHB患儿HBsAg损失的有用预测因子，为临床决策提供潜在指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.

联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1

京公网安备 11010802042870号

Book学术文献互助

Book学术文献互助群
群号：604180095

Book学术官方微信